An experimental and controversial treatment for Alzheimer’s disease is another step closer to full approval by the Food and Drug Administration. A panel of independent advisers voted 6-0 on Friday that Leqembi can benefit patients, a finding based on clinical trial data that showed it slowed cognitive decline by 27 percent over an 18-month period. However, the drug does not reverse Alzheimer’s and some experts have raised questions about serious side effects and the $25,000-a-year price tag.
Read it at Reuters
